Home・Stock List・Erasca Inc

Erasca Inc

Closed

19.11 -1.24

Buy Sell

Overview

Share price change

24h

Current

Min

Max

19.37

Key metrics
By Trading Economics
Income	-154M -183M
EPS	-0.6
Employees	103
EBITDA	-151M -183M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+17.22% upside

Dividends
By Acuity
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	3.3B 6.5B
Previous open	20.35
Previous close	19.11

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Saturday's session, building on Friday's gains. The price movement aligns with Ethereum's upward trend.

25 Jul 2026, 23:42 UTC

Personal Income MoM Data Release on July 30, 2026, Forecasts Modest Growth Amid Ongoing Market Volatility and Geopolitical Concerns.

25 Jul 2026, 23:42 UTC

U.S. Personal Spending Expected to Rise 0.4% in June Amid Inflation and Geopolitical Tensions Impacting Consumer Behavior

25 Jul 2026, 23:42 UTC

Market Awaits Key PCE Price Index Data on July 30, 2026, Amid Rising Inflation Concerns and Potential Impact on Federal Reserve Policy.

25 Jul 2026, 23:42 UTC

South Korea's exports surge 70.9% in June, with August release expected to reveal continued growth amid cautious investor sentiment due to inflation and geopolitical tensions.

25 Jul 2026, 23:42 UTC

U.S. GDP Price Index Set for 3.7% Increase Amid Cautious Optimism and Inflation Concerns Ahead of Key Federal Reserve Policy Decisions.

25 Jul 2026, 23:42 UTC

Traders Brace for PCE Price Index Release Amid Geopolitical Tensions and Inflation Concerns, Anticipating 0.4% Increase

25 Jul 2026, 23:42 UTC

Core PCE Price Index MoM Release on July 30, 2026, Expected to Show Modest 0.1% Increase Amid Inflation Concerns and Market Sensitivity.

25 Jul 2026, 23:42 UTC

U.S. Q2 2026 GDP Growth Rate Release Expected at 2.3% Amid Positive Economic Sentiment and Geopolitical Concerns

25 Jul 2026, 23:32 UTC

S&P/Case-Shiller Home Price Index Set for July Release Amidst Cautious Market Sentiment and Inflation Concerns

25 Jul 2026, 23:32 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is under scrutiny as analysts anticipate continued deficits amid rising imports and geopolitical tensions.

25 Jul 2026, 23:31 UTC

"Cryptocurrency Gains Amid Geopolitical Tensions; European Stocks Shift and Fed's Rate Decision Looms"

25 Jul 2026, 23:31 UTC

Cryptocurrency gains amid European market reassessment and bond turmoil, as investors brace for the Fed's interest rate decision and Japan's fiscal policy shift.

25 Jul 2026, 23:31 UTC

Bitcoin and Ethereum rise amid shifting European equity markets, Japan's fiscal policy changes, and looming Federal Reserve interest rate decision.

25 Jul 2026, 23:31 UTC

Cryptocurrency prices rise as Bitcoin and Ethereum gain, while European equity markets face shifts and Japan's fiscal policy change looms ahead of the Federal Reserve's interest rate decision.

25 Jul 2026, 23:24 UTC

Mexico's Q2 GDP Growth Rate Release on July 30 Sparks Cautious Optimism Amid Strong Services PMI Performance.

25 Jul 2026, 23:24 UTC

Brazil's Unemployment Rate Expected to Remain Stable or Improve in June 2026 Amid Cautious Optimism and Economic Recovery Concerns

25 Jul 2026, 23:13 UTC

Mexico's Q2 2026 GDP Growth Rate Release on July 30 Sparks Caution Amid Geopolitical Tensions and Trade Tariff Concerns.

25 Jul 2026, 23:13 UTC

Japan's Industrial Production MoM data for June 2026 set to release on July 30, with a modest increase of 0.7% anticipated amid mixed economic sentiment and rising inflation concerns.

25 Jul 2026, 23:13 UTC

Germany's Inflation Rate Release on July 30, 2026: Market Anticipates Continued Pressure Amid Mixed Economic Signals.

25 Jul 2026, 23:13 UTC

Japan's Retail Sales Expected to Rise 2.8% YoY Amid Concerns Over Consumer Spending and Economic Recovery Challenges

25 Jul 2026, 23:13 UTC

Germany's July Inflation Rate Expected to Rise 0.7% Amid Mixed Economic Sentiment and Rising Oil Prices

25 Jul 2026, 23:03 UTC

Wholesale Inventories MoM Advance Data Set for Release Amid Mixed Economic Sentiment and Geopolitical Tensions, Forecasting 0.2% Increase.

25 Jul 2026, 23:03 UTC

U.S. Goods Trade Balance Release Expected to Show $98 Billion Deficit Amid Tariff Concerns and Inflation Pressures

25 Jul 2026, 23:03 UTC

U.S. Retail Inventories Ex Autos Data Release on July 28, Amid Weakening Consumer Spending and Inflation Concerns

25 Jul 2026, 23:01 UTC

Avalanche continues to trade higher, reflecting strong performance since Friday's close. Earlier, it peaked over 8%, remaining above its 20-day moving average.

25 Jul 2026, 22:51 UTC

Japan's June 2026 unemployment rate forecast at 2.5% amid rising inflation concerns and market volatility ahead of release on July 30, signaling mixed investor sentiment.

25 Jul 2026, 22:42 UTC

Durable Goods Orders Report on July 27, 2026 Expected to Show Recovery Amidst Market Volatility and Geopolitical Tensions.

25 Jul 2026, 22:42 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.9% in June Amid Cautious Optimism and External Economic Pressures

25 Jul 2026, 22:42 UTC

Mortgage Rates Hit 6.69% Amid Rising Treasury Yields and Inflation Concerns, Influencing Real Estate Market Dynamics

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

17.22% upside

12 Months Forecast

Average 22.4 USD 17.22%

High 30 USD

Low 18 USD

Based on 10 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Erasca Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.